Biogen Idec, Inc. (Massachusetts) Release: New TYSABRI® Data Show Earlier Treatment and Longer-Term Use Result in Significant Reductions in MS Disease Activity

Published: Oct 03, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WESTON, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) today announced results from several new analyses of TYSABRI® (natalizumab) data that demonstrate its effectiveness in reducing multiple sclerosis (MS) disease activity. This effect was particularly significant in people with relapsing MS who initiated treatment when they had lower Expanded Disability Status Scale (EDSS) scores as well as in those who have been treated for more than two years. These data will be presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark from 2-5 October.

Help employers find you! Check out all the jobs and post your resume.

Back to news